2 Growth Stocks to Buy and Hold for 10 Years

Group 1: Market Trends - Current popular themes on Wall Street include artificial intelligence, weight management medicines, and the impact of tariffs on equities and the economy [1] - The market is expected to continue delivering competitive returns over the next decade despite changing trends [1] Group 2: Shopify - Shopify has outperformed the market since its IPO 10 years ago, maintaining a strong position in the fast-growing e-commerce sector with over 12% market share in the U.S. by gross merchandise volume as of the end of 2024 [4][5] - The company's competitive edge is driven by high switching costs and network effects, making it difficult for merchants to leave the platform once they have invested time and resources [6] - Shopify's app store enhances its attractiveness to merchants, as it offers thousands of customization options [7] - The e-commerce market is expected to grow, providing Shopify with a larger consumer base, although over 80% of retail transactions still occur offline in the U.S. [8] - Despite not being profitable currently, Shopify has made significant operational changes that are expected to lead to consistent profitability in the coming years [9] - The stock is considered a buy due to its long-term growth prospects, despite potential short-term volatility [10] Group 3: Vertex Pharmaceuticals - Vertex Pharmaceuticals has faced challenges over the past year, including clinical setbacks and competition from illegal copies of its medicines in Russia, leading to lower-than-expected sales [11] - The company remains a leader in cystic fibrosis treatments, with its products targeting the underlying causes of the disease [13] - Vertex's new product, Journavx, has potential to generate significant revenue, estimated at $2.9 billion by 2030, due to high unmet needs in non-opioid pain treatments [14] - The company plans to expand its product lineup, including a potential type 1 diabetes treatment, and has a strong pipeline of early- and late-stage programs [15] - Vertex is expected to deliver superior returns through 2035, driven by its strong cystic fibrosis franchise and new product launches [15]